Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC1456 in Ovarian Cancer Surgery
NCT03011320Phase 1Completed
- Sponsor
- Endocyte
- Start
- Jan 2017
- Primary completion
- Dec 2017
- Modality
- Antibody-Drug Conjugates (ADCs), Peptides, Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ec1456 in ovarian cancer (4 cohorts), sponsored by Endocyte. Primary endpoint: Tumor penetration of EC1456 in frozen tissue at 18 months. Started Jan 2017; status: completed.
02
Drugs
ec1456
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03011320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011320.